ClinicalTrials.gg
CompletedNCT06227975Updated May 13, 2024

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

A Phase 1 interventional study of [14C]-BMS-986368 in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the pharmacokinetics (PK), metabolites, route of elimination, and mass balance of BMS-986368 in healthy male participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • ADME
  • Healthy male volunteers
  • Pharmacokinetics
  • BMS-986368
  • CC-97489
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants as determined by no deviations from normal in medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations, as assessed by the investigator.
  • of 18.0 to 35.0 kg/m2, inclusive. Body mass index = weight (kg)/(height[m])\^2

Exclusion criteria

Exclusion Criteria:

  • History of hypokalemia.
  • Any significant acute or chronic medical illness as determined by the investigator.
  • Participant has a history of syncope in the year prior to Day 1.

Other protocol-defined incusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [14C]-BMS-986368

    Drug: [14C]-BMS-986368

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 15

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 15

  3. Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 15

  4. Total Radioactivity (TRA)

    Time frame: Up to Day 30

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Up to Day 36

  2. Number of participants with Serious AEs (SAEs)

    Time frame: Up to Day 36

  3. Number of participants with AEs leading to discontinuation

    Time frame: Up to Day 36

  4. Number of participants with vital sign abnormalities

    Time frame: Up to Day 30

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 30

  6. Number of participants with physical examination abnormalities

    Time frame: Up to Day 30

  7. Number of participants with clinical laboratory test abnormalities

    Time frame: Up to Day 30

07

Study locations

1 site
  • Local Institution - 0001
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Apr 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Jan 29, 2024
StartActual
Feb 2, 2024
Primary completionActual
Apr 3, 2024
CompletionActual
Apr 3, 2024
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06227975
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Feb 2, 2024
Primary completion
Apr 3, 2024
Completion
Apr 3, 2024
Last update
May 13, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irafamdastat

Start the discussion